Literature DB >> 2585028

The intracerebral penetration of intraventricularly administered methotrexate: a quantitative autoradiographic study.

S A Grossman1, C S Reinhard, H L Loats.   

Abstract

The local concentration and distribution of methotrexate following intraventricular administration were studied in the brains of New Zealand White rabbits. Tritiated methotrexate was injected through subcutaneous reservoirs connected to ventricular catheters, the animals were sacrificed one hour after administration of the drug, and the distribution of the radiolabelled compound was assessed using quantitative autoradiographic techniques. The intracerebral distribution of tritiated inulin delivered in an identical fashion was studied for comparison. One hour after intraventricular administration of radiolabelled methotrexate or inulin approximately 40% of the area of the brain sections contained appreciable concentrations of the radiolabelled tracer. Gray matter adjacent to the cerebrospinal fluid, including the hippocampus, thalamus, caudate nucleus, and periaquaductal gray contained the highest concentrations of 3H-methotrexate. Large white matter tracts contained smaller amounts of tracer activity. The rapid and extensive penetration of intraventricularly administered methotrexate and inulin into normal brain parenchyma and the high methotrexate concentrations in specific regions of the brain provide insight into the pathogenesis of methotrexate-induced neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2585028     DOI: 10.1007/bf02147089

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  26 in total

1.  Leukoencephalopathy following chemotherapy for rhabdomyosarcoma: reversibility of cerebral changes demonstrated by computed tomography.

Authors:  J E Fusner; D G Poplack; P A Pizzo; G Di Chiro
Journal:  J Pediatr       Date:  1977-07       Impact factor: 4.406

2.  Transient, severe periventricular hypodensity after leukemic prophylaxis with cranial irradiation and intrathecal methotrexate.

Authors:  L R Wendling; W A Bleyer; G Di Chiro; S K McIlvanie
Journal:  J Comput Assist Tomogr       Date:  1978-09       Impact factor: 1.826

3.  Spinal cord penetration of intrathecally administered cytarabine and methotrexate: a quantitative autoradiographic study.

Authors:  P A Burch; S A Grossman; C S Reinhard
Journal:  J Natl Cancer Inst       Date:  1988-10-05       Impact factor: 13.506

4.  Proceedings: Parenchymatous degeneration of the central nervous system in childhood leukemia.

Authors:  B Hendin; D C DeVivo; R Torack; M E Lell; A H Ragab; T J Vietti
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

5.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

6.  Leukoencephalopathy following the administration of methotrexate into the cerebrospinal fluid in the treatment of primary brain tumors.

Authors:  H Norrell; C B Wilson; D E Slagel; D B Clark
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

7.  Current status of intrathecal chemotherapy for human meningeal neoplasms.

Authors:  W A Bleyer
Journal:  Natl Cancer Inst Monogr       Date:  1977-12

8.  Ultrastructure of the ventricular walls. Three-dimensional study of regional specialization.

Authors:  A Weindl; R J Joynt
Journal:  Arch Neurol       Date:  1972-05

9.  Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.

Authors:  W R Shapiro; D F Young; B M Mehta
Journal:  N Engl J Med       Date:  1975-07-24       Impact factor: 91.245

10.  Cerebrospinal fluid flow abnormalities in patients with neoplastic meningitis. An evaluation using 111indium-DTPA ventriculography.

Authors:  S A Grossman; D L Trump; D C Chen; G Thompson; E E Camargo
Journal:  Am J Med       Date:  1982-11       Impact factor: 4.965

View more
  8 in total

1.  A radiotherapy technique to limit dose to neural progenitor cell niches without compromising tumor coverage.

Authors:  Kristin J Redmond; Pragathi Achanta; Stuart A Grossman; Michael Armour; Juvenal Reyes; Lawrence Kleinberg; Erik Tryggestad; Alfredo Quinones-Hinojosa; Eric C Ford
Journal:  J Neurooncol       Date:  2011-02-14       Impact factor: 4.130

2.  Association between radiation dose to neuronal progenitor cell niches and temporal lobes and performance on neuropsychological testing in children: a prospective study.

Authors:  Kristin J Redmond; E Mark Mahone; Stephanie Terezakis; Omar Ishaq; Eric Ford; Todd McNutt; Lawrence Kleinberg; Kenneth J Cohen; Moody Wharam; Alena Horska
Journal:  Neuro Oncol       Date:  2013-01-14       Impact factor: 12.300

Review 3.  Central nervous system prophylaxis in non-Hodgkin lymphoma: who, what, and when?

Authors:  Chan Yoon Cheah; John F Seymour
Journal:  Curr Oncol Rep       Date:  2015-06       Impact factor: 5.075

4.  Direct delivery of platinum-based antineoplastics to the central nervous system: a toxicity and ultrastructural study.

Authors:  A Olivi; M Gilbert; K L Duncan; B Corden; D Lenartz; H Brem
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 5.  Updates in the management of brain metastases.

Authors:  Nils D Arvold; Eudocia Q Lee; Minesh P Mehta; Kim Margolin; Brian M Alexander; Nancy U Lin; Carey K Anders; Riccardo Soffietti; D Ross Camidge; Michael A Vogelbaum; Ian F Dunn; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2016-08       Impact factor: 12.300

Review 6.  Recent Advancements of Treatment for Leptomeningeal Carcinomatosis.

Authors:  Ho-Shin Gwak; Sang Hyun Lee; Weon Seo Park; Sang Hoon Shin; Heon Yoo; Seung Hoon Lee
Journal:  J Korean Neurosurg Soc       Date:  2015-07-31

7.  Meningeal carcinomatosis: a metastasis from gastroesophageal junction adenocarcinoma.

Authors:  Tanya Dam; Aftab Mahmood; Kenneth Linville; Michael Bailey; Salim Surani
Journal:  Case Rep Med       Date:  2013-12-19

Review 8.  Neoplastic meningitis.

Authors:  L Kim; M J Glantz
Journal:  Curr Treat Options Oncol       Date:  2001-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.